The fact that Neuren are announcing this confirms that they appreciate that the Acadia bad press has hurt perceptions of the Neuren deal.
Great news for Acadia and Neuren. This puts a complete lid on the negative press and provides surety that Nuplazid is here to stay. This secures Acaida as a financially secure partner for Neuren to bring Trofinetide through to market.
Let's see what the market thinks!
Ann: FDA reaffirms positive benefit-risk of ACADIA's NUPLAZID, page-2
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$16.93 |
Change
-0.360(2.08%) |
Mkt cap ! $2.133B | |||
| Open | High | Low | Value | Volume |
| $17.08 | $17.67 | $16.93 | $6.897M | 401.2K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 2660 | $16.93 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $17.07 | 1994 | 2 |
View Market Depth
| Last trade - 16.10pm 01/08/2025 (20 minute delay) ? |
| NEU (ASX) Chart |